Program, Speakers and Abstract Submissions

Vaccine Technology X

Program Agenda

Keynote Speakers

Katie Ewer
Senior Project Leader, malaria vaccines
GSK

Development, launch, and introduction of malaria vaccines

Gian Gandhi
Deputy Director, Immunization, Global Development
Gates Foundation

Global immunization: Charting a course forward in a period of deep uncertainty

Global immunization has long stood as a triumph of science and public health, driven by decades of innovation in vaccine research, development, and delivery. Yet the world now stands at a critical inflection point. Over the past two decades, scientific ingenuity—paired with strategic investment and equitable access models—has transformed population health. But the systems and partnerships that fueled these successes are now being tested by converging crises: geopolitical instability, climate shocks, shifting donor priorities, misinformation, and the lingering effects of the COVID-19 pandemic. As traditional models of financing and coordination strain under new pressures, the path forward demands fresh thinking and adaptive leadership.

This keynote presentation will take stock of what has worked well—scientific innovation, effective public–private partnerships, sustained global cooperation, innovative financing models, and the rapid introduction of novel vaccines. It will explore how to preserve these achievements while building the agility needed to navigate a rapidly changing world. The talk will chart a course toward maximizing vaccine access and coverage in an era of uncertainty—by reimagining global solidarity, service delivery models, and sustainable financing, and by leveraging data and innovation to sustain and amplify the public health impact of immunization over the next two decades.

Amadou Sall
Executive Director, Manufacturing and Supply Chain
CEPI

African Vaccine Manufacturing Network

Session Descriptions

Next Gen platforms and Novel technologies: Accelerating Vaccine Innovation for the Future

Session Chairs:
Cyrielle Fougeroux, Adaptvac, Denmark
Florian Krammer, Icahn School of Medicine at Mount Sinai, USA 
 
This session dives into the latest vaccine platforms and cutting-edge technologies, from
vector-based vaccines to modular antigen display approaches. By embracing next-
generation technologies, such as nanoparticle vaccines and novel expression systems,
the industry is accelerating innovation to meet global vaccine challenges faster and
more efficiently than ever before.

Bioprocessing Breakthroughs, AI Integration, and Systems Biology: Accelerating Vaccine Innovation in Manufacturing

Session Chairs:
Laura Pack, Moderna, USA
Kumar Namdev, Sanofi, USA

This session explores how breakthroughs in bioprocessing technologies, artificial
intelligence, regulatory sciences, protein (antigen) design, and computational biology
are transforming vaccine development and manufacturing. Key discussions will highlight
predictive analytics, high-throughput screening, and computational modeling in
enhancing manufacturability, process robustness, and cost efficiency. The session will
also showcase real-world applications demonstrating how these advancements are
accelerating development timelines, improving scalability, and shaping next-generation
vaccine production. By integrating these innovations, the field is advancing toward more
automated, data-driven, and scalable solutions, ensuring vaccines are developed and
produced with greater efficiency, precision, and accessibility.

Vaccine analytical tools and PAT: Accelerating Vaccine Innovation through Precision 

Session Chairs:
Jamie Wagner, Merck, USA
Laura Cervera Gracia, Universitat Autònoma de Barcelonna, Spain

Focusing on the role of advanced analytical tools and Process Analytical Technology
(PAT), tools that are essential for accelerating the innovation pipeline and improving the
reliability of vaccine manufacturing, this session covers real-time monitoring techniques,
data-driven quality control, and regulatory innovations that ensure vaccines are safe,
effective, and produced at scale.

Lessons from Animal Health: Accelerating Vaccine Innovation for Human Health

Session Chairs:
Abby Patterson, Boehringer-Ingelheim, USA
Diego Fontana, Laboratorio de Desarrollo Biotecnologico, Argentina

This session demonstrates how lessons from animal vaccine development can
accelerate innovation in human health. By studying immune response mechanisms,
viral evolution, and deployment strategies in animal health, participants  gain insights
into faster and more effective vaccine development for human diseases.

Formulation, Delivery, Device: Accelerating Vaccine Innovation in Administration and Accessibility

Session Chairs:
Jeff Blue, Merck, USA
Nicole Payton, Asta Zeneca

This session explores how novel formulations, delivery methods, and devices are
enhancing the speed, efficiency, and accessibility of vaccines. From advanced
stabilizers to cutting-edge delivery systems like microneedles and needle-free injectors,
these innovations are crucial to accelerating the development and distribution of
effective vaccines globally.

Regional Development and Manufacturing Capacity Building: Accelerating Vaccine Innovation for Global Equity

Session Chairs:
Laura Palomares, Instituto de Biotecnologia UNAM, Mexico
Acep Riza, BioFarma, Indonesia

This session focuses on the critical role of building regional development and
manufacturing capacity to accelerate vaccine innovation. Topics will highlight successes
from LMIC manufacturers in conducting technology transfer, building local infrastructure
to fill supply gaps, and novel regulatory strategies to ensure that vaccine production is
scalable, sustainable, and accessible to all regions, particularly low- and middle-income
countries.

Nucleic Acid based vaccines: Accelerating Vaccine Innovation with Next Generation Genetic Platforms

Session Chairs:
Kate Broderick, USA
Duccio Medini

This session will explore the continued evolution of nucleic acid-based vaccines,
highlighting the unmatched flexibility and speed offered by nucleic acid-based platforms.
Attendees will gain insights into cutting-edge advancements and innovations that have
emerged in the post-COVID era. The session will also cover how these technologies are
positioned to continue evolving vaccine development, enabling rapid responses to
emerging infectious diseases and pandemics. From personalized vaccines to scalable
platforms, the future of immunization is unfolding faster than ever, and this session will
delve into what lies ahead for accelerating vaccine innovation with nucleic acid-based
platforms.

Environmental sustainability: Accelerating Vaccine Innovation with Green Practices

Session Chairs:
Yinka Oyinloye, Astrazeneca, UK
Magali Barbaroux, Sartorius, France  

This session explores how innovations in environmental sustainability are
complementing the acceleration of vaccine innovation. Experts will discuss the use of
energy-efficient processes, sustainable material sourcing, and waste reduction to
minimize the environmental impact of vaccine manufacturing, all while maintaining the
speed and scalability of production.

Workshop Descriptions

Shifting Global Vaccine Priorities: Funding in a New Political Landscape

Workshop Chair:
Piper Trelsedt, Gates MRI 
 
Over the past 20 years, the acceleration of vaccine innovation has been supported by a
diverse network of funders, spanning governments, philanthropic organizations,
multilateral agencies, and industry. With the changing geopolitical goals and the
resulting gaps in global vaccine funding, new questions arise around how priorities are
shifting and which organizations are stepping in to address unmet needs. This session
will bring together a panel of global funders to discuss how their strategies are evolving
in light of these changes—whether by redirecting resources, strengthening regional
initiatives, or identifying new areas of focus to sustain innovation. An introductory expert
panel will set the scene, followed by an interactive discussion where the audience will
have the opportunity to engage with funders directly and explore how shifting priorities
may shape the next phase of vaccine development.

Bringing vaccines into market - this is how we do it… Part 2

Workshop Chair:
Manon Cox, NextWave Bio

Coming soon.

20 Years On: Breakthroughs, Challenges, and the Future of Vaccine Technology

Workshop Chair:
Tarit Mukhopadhyay, Merck

Coming soon.

Bringing next gen adjuvants to market

Workshop Chair:
Dennis Christensen, Croda

Over the past decades, exogenous adjuvants have increasingly been part of the new
and improved vaccines. The COVID-19 pandemic accelerated the development of new
adjuvants and 'mimics' of those already present in licensed vaccines, to increase
accessibility of known technologies. The increased interest for adjuvant technologies
accommodating the functional and regulatory demands for novel vaccines has
increased the effort to develop and make available said vaccine adjuvants for both
preclinical and clinical vaccine development programs. In the present session we will
discuss the opportunities and challenges related to the development of novel vaccine
adjuvants and making them broadly accessible. An introductory expert panel discussion
will set the scene followed by an interactive roundtable, where the audience will also
have the opportunity to challenge the expert panelist.

Vaccine Innovation and Leadership: Building a Career for Global Impact

Workshop Chair:
Linda Lau, The University of Queensland

Leadership is about influencing others, mobilizing people, and leveraging resources to
create meaningful impact. It isn't developed overnight, but through consistent,
intentional practice—small, positive habits built over time. This interactive workshop is
designed to support graduate students and early career researchers as they step into
leadership roles—whether coordinating projects, supervising students, mentoring peers,
or contributing to institutional and global initiatives. As you prepare for future roles in
academia, industry, or government, growing as a leader becomes essential. Through a
mix of practical exercises, peer discussion, and guided reflection, you’ll explore core
leadership skills such as strategic thinking, organizational influence, effective
communication, team dynamics, decision-making, and managing upward. The session
also builds on your commitment to advancing vaccine innovations for global health,
equipping you with tools and insights to lead with clarity and purpose. Grow to
lead—intentionally, confidently, and with impact.

Call for Abstracts

Abstracts (one page maximum) whose subject area is in the Technical Topics listed above are invited.  The abstract should include specific results and conclusions to allow a scientific assessment of the proposed oral presentation.

Please choose the most relevant session topic as noted in the sessions listed above for which you are submitted your oral or poster abstract.

Abstracts must be submitted electronically here and prepared according to this template: docx or doc.

Oral abstract submission deadline: October 31, 2025

Poster abstract submission deadline: December 1, 2025

  • To ensure receipt of mailings regarding your submission, please add ‘do_not_reply@linklings.com‘ to your address book.
  • Abstracts of all presentations will be made available to conference participants prior to the start of the conference.

Awards will be presented to the top student posters.

Poster Guidelines

The best posters display a succinct statement of major conclusions at the beginning, followed by supporting text in later segments and a brief summary at the end. Click here for instructions and more information.

Poster Size: 1.0 Meter wide and 1.5 meters in Length (Portrait style)

  • Request for Next Mailing

    Please Sign-In to your account to Request A Mailing.
  • Page Sections

  • Add Email

    To ensure receipt of ECI mailings, please add 'eci@informz.net' to your address book.
  • REGISTRATION SCAM ALERT

    Unless otherwise indicated, ECI will make your hotel reservation directly with the conference hotel after your registration is confirmed.

    Some conference participants have received fraudulent emails claiming to be from Docusign, asking them to confirm their registration. Please disregard and delete these emails. Do not click on any links contained in them.

    ECI will never contact you via telephone to make a payment, we do not use Docusign, and we do not accept PayPal. If anyone contacts you to make a reservation through a third party, please notify ECI at info@engconfintl.org.

  • Electronic Travel Authorization

    Travelers from 54 countries now are required to complete an online pre-travel check to enter the U.K.

    If your flight takes you through the UK, please read this.

  • Scam Alert!

    Unless otherwise indicated, ECI will make your hotel reservation directly with the conference hotel after your registration is confirmed. ECI will never contact you via telephone to make a payment and we do not accept PayPal. If anyone contacts you to make a reservation through a third party, please notify ECI at info@engconfintl.org.